Abstract
Objective
To evaluate the efficacy of Bawu Decoction (八物汤, BWD, Palmul-tang in Korean) against benign prostatic hyperplasia (BPH).
Methods
Twenty-four male Wistar rats were divided into 4 groups, with 6 rats in each group. The 4 study groups included sham-operated group (CON), BPH model group, fifinasteride-treated group, and BWD-treated group. All the groups except CON group received a subcutaneous injection of 10 mg/kg of testosterone, while CON group received saline. Finasteride at a dose of 5 mg/kg was administered to the finasteride-treated group for a period of 4 weeks. BWD group received BWD at a dose of 200 mg/kg for 4 weeks. The prostatic weight, prostate weight to body weight ratio, relative prostate weight ratio, serum testosterone and dihydrotestosterone (DHT) level, and histological analysis of prostatic tissue were analyzed.
Results
Compared to BPH model group, BWD administration was associated with reductions in prostatic weight, prostate and relative prostate weight ratio weight to body weight ratio (P<0.05). The concentration of serum testosterone and DHT were higher in BPH group compared with CON group (P<0.05). Administration of finasteride and BWD suppressed the elevation of serum testosterone and DHT levels signifificantly (both P<0.05). In addition, BWD suppressed the growth of prostatic tissue (P<0.05).
Conclusion
BWD has suppressant effects on development of BPH through inhibition of serum testosterone and DHT.
Similar content being viewed by others
References
de Lourdes Arruzazabala M, Molina V, Mas R, Carbajal D, Marrero D, Gonzalez V, et al. Effects of coconut oil on testosterone-induced prostatic hyperplasia in Sprague-Dawley rats. J Pharm Pharmacol 2007;59:995–999.
Keoghane SR. Quality of life assessment in patients after laser prostatectomy. Br J Urol 1998;81:656–657.
Steenkamp V, Gouws MC, Gulumian M, Elgorashi EE, van Staden J. Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis. J Ethnopharmacol 2006;103:71–75.
Isaacs JT. Etiology of benign prostatic hyperplasia. Eur Urol 1994;25 (Suppl) 1:6–9.
Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359–1367.
Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyak MJ, O’Leary MP, et al. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 1995;154:205–206.
Djavan B, Eckersberger E, Finkelstein J, Espinosa G, Sadri H, Brandner R, et al. Benign prostatic hyperplasia: current clinical practice. Prim Care 2010;37:583–597, ix.
Lepor H. Benign prostatic hyperplasia. J Urol 1995;153:1540–1542.
Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol 2011;13:20–33.
Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005;40:121–128.
Patel AK, Chapple CR. Benign prostatic hyperplasia: treatment in primary care. Br Med J 2006;333:535–539.
Uygur MC, Gur E, Arik AI, Altug U, Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia 1998;30:5–10.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr., Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–2398.
Bae JS, Park HS, Park JW, Li SH, Chun YS. Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signaling. J Nat Med 2012;66:476–485.
Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 2006;66:453–463.
Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, et al. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A 2011;108:3755–3760.
Jeon HJ, Chung KS, An HJ. Anti-proliferation effects of Cistanches salsa on the progression of benign prostatic hyperplasia. Ca J Physiol Pharmacol 2016;94:104–111.
Maggi CA, Manzini S, Giuliani S, Meli A. Infravesical outflow obstruction in rats: a comparison of two models. Gen Pharmacol 1989;20:345–349.
Chung KS, Shin SJ, Lee NY, Cheon SY, Park W, Sun SH, et al. Anti-proliferation effects of garlic (Allium sativum L.) on the progression of benign prostatic hyperplasia. Phytother Res 2016;30:1197–1203.
Flannery MT, Ramsdell J, Ranhosky A, Davidai G, Ruoff G. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting. Curr Med Res Opin 2006;22:721–730.
Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202–1216.
Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33–50.
Sun H, Li TJ, Sun LN, Qiu Y, Huang BB, Yi B, et al. Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats. J Ethnopharmacol 2008;115:203–208.
McConnell JD. The pathophysiology of benign prostatic hyperplasia. J Androl 1991;12:356–363.
Berry SJ, Strandberg JD, Saunders WJ, Coffey DS. Development of canine benign prostatic hyperplasia with age. Prostate 1986;9:363–373.
Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998;22:1073–1077.
Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19:413–425.
Brendler CB, Berry SJ, Ewing LL, McCullough AR, Cochran RC, Strandberg JD, et al. Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. J Clin Invest 1983;71:1114–1123.
Krieg M, Bartsch W, Thomsen M, Voigt KD. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem 1983;19:155–161.
Li S. Exploring traditional Chinese medicine by a novel therapeutic concept of network target. Chin J Integr Med 2016;22:647–652.
Hong ZF, Lin JM, Zhong XY, Li Y, Zhou JH, Xu W, et al. Qianliening capsule (前列宁胶囊) inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis. Chin J Integr Med 2012;18:824–830.
Huang YP, Du J, Hong ZF, Chen ZQ, Wu JF, Zhao JY. Effects of Kangquan Recipe (康泉方) on sex steroids and cell proliferation in rats with benign prostatic hyperplasia. Chin J Integr Med 2009;15:289–292.
Joo Jinman KD, Baek Seunghee, Kim Eunha. The effect of Palmultang (八物湯) on the ovarian functions and differential gene expression of caspase-3, MAPK and MPG in female mice. J Orient Obstetr Gynecol 2007;20:91–110.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning(NRF- 2016R1C1B2011827)
Rights and permissions
About this article
Cite this article
Eom, JH., Cheon, SY., Chung, KS. et al. Bawu decoction (八物汤) ameliorates benign prostatic hyperplasia in rats. Chin. J. Integr. Med. 23, 611–616 (2017). https://doi.org/10.1007/s11655-016-2528-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-016-2528-8